(:FREQ)
Business Focus: N/A
Oct 08, 2023 12:03 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, FREQ
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: American Equity Investment Life...
Oct 06, 2023 02:14 pm ET
FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Frequency Therapeutics, Inc. (NasdaqGS: FREQ) to Korro Bio, Inc. Under the terms of the proposed transaction, pre-merger Frequency Therapeutics stockholders are expected to own approximately 8% of the combined company. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Aug 10, 2023 04:01 pm ET
Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023.
Aug 07, 2023 05:00 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – EMAN, FREQ, DEN, BG
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Aug 01, 2023 03:37 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTX
NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 31, 2023 05:32 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – FREQ, BG, EMAN, DEN
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jul 26, 2023 01:39 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAIC, BG, DEN, FREQ
NEW YORK, July 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 25, 2023 10:10 am ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – EMAN, FREQ, DEN, BG
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jul 23, 2023 10:57 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FREQ, HCCI, CCF
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Frequency Therapeutics, Inc. (NASDAQ:...
Jul 21, 2023 10:53 am ET
FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Frequency Therapeutics, Inc. (NasdaqGS: FREQ) to Korro Bio, Inc. Under the terms of the proposed transaction, pre-merger Frequency Therapeutics stockholders are expected to own approximately 8% of the combined company. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jul 18, 2023 10:39 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQ
NEW YORK, July 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 17, 2023 05:16 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – FREQ, EMAN, BG, DEN
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jul 16, 2023 12:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, FREQ, TALS
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chinook Therapeutics, Inc. (NASDAQ:...
Jul 15, 2023 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of AJX, AEL, DEN, and FREQ
Great Ajax Corporation (NYSE: AJX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of AJX to Ellington Financial Inc. for 0.5308 shares of Ellington Financial Inc. common...
Jul 14, 2023 10:00 am ET
FREQ Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Frequency Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Frequency Therapeutics, Inc. (NASDAQ: FREQ) and Korro Bio, Inc. is fair to Frequency shareholders. Pre-merger Frequency shareholders are expected to own approximately 8% of the combined company.
Jul 14, 2023 06:30 am ET
Korro Bio and Frequency Therapeutics Announce Merger Agreement
Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs, is expected to operate under Korro Bio, Inc. and will apply to trade on Nasdaq under the ticker symbol “KRRO”.
May 12, 2023 04:01 pm ET
Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2023.
Mar 10, 2023 07:30 am ET
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.
Feb 27, 2023 07:30 am ET
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that interim Chief Executive Officer and Chief Scientific Officer Christopher Loose, Ph.D., will present at the following March healthcare investor conferences:
Feb 13, 2023 08:05 am ET
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss (SNHL).
Dec 19, 2022 07:30 am ET
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has established a Clinical Advisory Board to help guide its remyelination in multiple sclerosis (MS) program. Comprised of leading experts from across the neurosciences, the Clinical Advisory Board will support clinical development and translation efforts as the Company advances its small molecule therapeutic candidate through human studies. The Company plans a regulatory filing for it
Dec 15, 2022 07:30 am ET
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the Company’s second hearing restoration candidate for sensorineural hearing loss (SNHL).
Nov 29, 2022 10:05 am ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Frequency Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Frequency Therapeutics, Inc. (NASDAQ: FREQ).
Nov 17, 2022 07:30 am ET
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it will host a virtual investor event on December 13, 2022, with a focus on FX-322, the Company’s lead hearing restoration candidate for acquired sensorineural hearing loss (SNHL). A Phase 2b study of FX-322 (FX-322-208) is fully enrolled with clinical results anticipated in the first quarter of 2023.
Nov 08, 2022 04:05 pm ET
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022.
Oct 12, 2022 07:30 am ET
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL). The FX-322-208 study, which enrolled 142 individuals, is designed to show improvement in a pre-specified measure of speech perception. The Company plans to release study data in the first quarter of 2023.
Aug 30, 2022 07:30 am ET
Frequency Therapeutics to Participate in September Investor and Medical Conferences
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that members of its management team will participate in investor and medical conferences later this month.
Aug 09, 2022 04:05 pm ET
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the second quarter ended June 30, 2022.
Jul 08, 2022 05:28 pm ET
Gainey McKenna & Egleston Investigates The Officers And Directors Of Frequency Therapeutics, Inc. (FREQ)
Gainey McKenna & Egleston announces that it is investigating the officers and directors of Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ: FREQ) for potential breaches of fiduciary duties, waste of corporate assets, and unjust...
May 18, 2022 07:30 am ET
Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose will present at the upcoming H.C. Wainwright Global Investment Conference.
May 04, 2022 04:30 pm ET
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2022.
Apr 22, 2022 07:30 am ET
Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose and Vice President of Discovery Biology Dr. Sanjay Magavi will participate in a fireside presentation at the B. Riley Securities’ Neuro & Ophthalmology Conference on April 28, 2022 at 3:30 pm ET.
Apr 18, 2022 09:31 am ET
Thinking about buying stock in Casa Systems, Vinco Ventures, Nordic American Tanker, Enservco, or Frequency Therapeutics?
NEW YORK, April 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CASA, BBIG, NAT, ENSV, and FREQ.
Mar 15, 2022 07:30 am ET
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2021.
Feb 28, 2022 07:30 am ET
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will participate in two upcoming investor conferences:
Jan 04, 2022 07:30 am ET
Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference
Mr. Lucchino’s presentation will take place on January 13th at 10:30 a.m. ET and will be followed by a question-and-answer session immediately thereafter. A live webcast of both the presentation and the breakout session can be accessed on the investors section of Frequency’s website, investors.frequencytx.com. A replay of the presentation will be posted on the Frequency website following the event.
Dec 09, 2021 07:30 am ET
Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today shared the results from its FX-322-113 study, a placebo-controlled trial evaluating the administration of FX-322 in subjects with severe sensorineural hearing loss (SNHL). In the study, FX-322 was associated with a hearing signal as shown by improvements by four subjects in a sentence-in-noise test.
Nov 15, 2021 07:30 am ET
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2021.
Nov 09, 2021 07:30 am ET
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Mul
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today will host a virtual R&D event. The webcast can be accessed here.
Oct 27, 2021 07:30 am ET
Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that the Company will be hosting a virtual R&D event on November 9, 2021.
Oct 21, 2021 07:30 am ET
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that the first subject has been dosed in a new FX-322 Phase 2b study (FX-322-208) being conducted in a refined population of individuals with SNHL.
Sep 22, 2021 07:30 am ET
Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore human function, today announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved statistically significant hearing improvements when evaluated 8 to 12 months following initial dosing.
Sep 08, 2021 07:30 am ET
Frequency Therapeutics to Present at Upcoming Investor Conferences
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present at the following investor conferences:
Aug 12, 2021 07:30 am ET
Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the second quarter ended June 30, 2021.
Aug 01, 2021 10:38 am ET
FREQUENCY DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency To Contact Him Directly To Discu
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ:FREQ) and reminds investors of the August 2, 2021 deadline to seek the role...
Jul 30, 2021 08:49 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of investors that purchased Frequency Therapeutics, Inc. (NASDAQ: FREQ) securities between November 16, 2020 and March 22, 2021, both dates inclusive (the “Class Period”). Investors have until August 2, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jul 30, 2021 07:19 pm ET
Frequency Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Frequency Therapeutics, Inc. (NASDAQ: FREQ) investors that acquired shares between November 16, 2020 and March 22, 2021. Investors have until July 13,...
Jul 30, 2021 11:30 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)
The Law Offices of Frank R. Cruz reminds investors of the upcoming August 2, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ:
Jul 30, 2021 10:00 am ET
FREQ Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) and certain of its officers, on behalf of...
Jul 29, 2021 04:02 pm ET
MONDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ
SAN DIEGO, July 29, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed on behalf of purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"). The Frequency Therapeutics class action lawsuit charges Frequency Therapeutics and certain of its executives with violations of the Securities Exchange Act of 1934. The Frequency Therapeutics class action lawsuit (Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933) was filed in the District of Mass
Jul 29, 2021 12:30 pm ET
FREQ DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Frequency Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Monday Deadline in Securities C
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”), of the important August 2,...
Jul 28, 2021 08:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Frequency, Athira, Full Truck, and Coinbase and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Frequency Therapeutics, Inc. (NASDAQ: FREQ), Athira Pharma, Inc. (NASDAQ: ATHA),...
Jul 28, 2021 07:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ
NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ) and certain of its officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 21-cv-11040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Frequency's common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"), seeking to pursue remedies
Jul 28, 2021 11:00 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)
BENSALEM, Pa., July 28, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming August 2, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period").
Jul 28, 2021 09:33 am ET
DEADLINE NEXT WEEK: Investors with Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ
Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed on behalf of purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”). The Frequency Therapeutics
Jul 27, 2021 11:15 am ET
DEADLINE ALERT for SPCE, FREQ, ACRX, and RLX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 26, 2021 09:45 pm ET
Jul 26, 2021 03:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FREQ
Pomerantz LLP announces that a class action lawsuit has been filed against Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ: FREQ) and certain of its officers. The class action, filed in the United States District Court for the...
Jul 26, 2021 02:12 pm ET
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors of a Securities Class Action Against Frequency, Inc. (NASDAQ: FREQ) and August 2 Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, reminds investors of a securities class action lawsuit against Frequency, Inc. (NASDAQ: FREQ) (“Frequency” or the “Company”) and its...
Jul 26, 2021 01:00 pm ET
DEADLINE ALERT for FREQ, ACRX, RLX, HMPT: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 25, 2021 10:34 am ET
FREQUENCY DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency To Contact Him Directly To Discu
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ:FREQ) and reminds investors of the August 2, 2021 deadline to seek the role...
Jul 23, 2021 01:30 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)
LOS ANGELES, July 23, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period").
Jul 21, 2021 08:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Frequency, DiDi, and CarLotz and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Frequency Therapeutics, Inc. (NASDAQ: FREQ), DiDi Global, Inc. (NYSE: DIDI), and...
Jul 21, 2021 11:00 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Frequency Therapeutics, Inc. (FREQ) Investors
LOS ANGELES, July 21, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"). Frequency investors have until August 2, 2021 to file a lead plaintiff motion.
Jul 21, 2021 07:06 am ET
(FREQ) Deadline Alert: Investors Interested in Being a Lead Plaintiff in Securities Fraud Class Action Lawsuit Against Frequency Therapeutics - Contact Johnson Fistel
SAN DIEGO, July 21, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Frequency Therapeutics, Inc. (NASDAQ: FREQ) ("Frequency Therapeutics " or the "Company"). The class action is on behalf of shareholders who purchased Frequency Therapeutics between November 16, 2020 and March 22, 2021 both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff in this class action, you must move the Court no later than August 2, 2021.
Jul 20, 2021 01:43 pm ET
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm Before August 2, 2021
The law firm of Kirby McInerney LLP reminds investors that a securities class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired Frequency Therapeutics, Inc. (“Frequency” or...
Jul 20, 2021 12:26 pm ET
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors of a Securities Class Action Against Frequency, Inc. (NASDAQ: FREQ) and August 2 Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, reminds investors of a securities class action lawsuit against Frequency, Inc. (NASDAQ: FREQ) (“Frequency” or the “Company”) and its Chief Executive Officer, David Lucchino, alleging violations of §§
Jul 20, 2021 11:30 am ET
DEADLINE ALERT for SPCE, FREQ, ACRX, and RLX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 20, 2021 10:00 am ET
FREQ, ACRX & RLX Class Action Reminders: Bronstein, Gewirtz & Grossman LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jul 19, 2021 05:03 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Frequency Therapeutics, Inc. Investors With Losses Over $100K to Secure Counsel Before Important August 2 Deadline in Securities Class Action – FREQ
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”), of the important August 2,...
Jul 19, 2021 04:00 pm ET
DEADLINE ALERT for FREQ, ACRX, RLX, HMPT: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 18, 2021 07:52 pm ET
FREQUENCY DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency To Contact Him Directly To Discu
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ:FREQ) and reminds investors of the August 2, 2021 deadline to seek the role...
Jul 18, 2021 09:50 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ
NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ) and certain of its officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 21-cv-11040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Frequency's common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"), seeking to pursue remedies
Jul 16, 2021 07:00 pm ET
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm Before August 2, 2021
The law firm of Kirby McInerney LLP announces that a securities class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ:
Jul 16, 2021 04:20 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Frequency Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important August 2 Deadline in Securities Class Action – FREQ
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”), of the important August 2, 2021 lead plaintiff deadline.
Jul 16, 2021 12:30 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Frequency Therapeutics, Inc....
Jul 15, 2021 06:08 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FREQ
Pomerantz LLP announces that a class action lawsuit has been filed against Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ: FREQ) and certain of its officers. The class action, filed in the United States District Court for the...
Jul 15, 2021 09:35 am ET
FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit
SAN DIEGO, July 15, 2021 /PRNewswire/ -- The Frequency Therapeutics, Inc. class action lawsuit charges Frequency Therapeutics and its CEO with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Frequency Therapeutics common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"). The Frequency Therapeutics class action lawsuit was commenced on June 3, 2021 in the District of Massachusetts and is captioned Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933. A similar lawsuit, captioned Hingston v. Frequency Therapeutics, Inc
Jul 14, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ubiquiti, Frequency, DiDi, and CarLotz and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ubiquiti, Inc. (NYSE: UI), Frequency Therapeutics, Inc. (NASDAQ: FREQ), DiDi...
Jul 13, 2021 11:30 am ET
DEADLINE ALERT for SPCE, FREQ, ACRX, and RLX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 12, 2021 06:27 pm ET
FREQUENCY THERAPEUTICS INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ
Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the District of Massachusetts on behalf of purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”).
Jul 12, 2021 06:18 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action – FREQ
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”), of the important August 2,...
Jul 12, 2021 01:00 pm ET
DEADLINE ALERT for FREQ, ACRX, RLX, HPMT: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 10, 2021 01:20 pm ET
Jul 10, 2021 07:15 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ
NEW YORK, July 10, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ) and certain of its officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 21-cv-11040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Frequency's common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"), seeking to pursue remedies
Jul 09, 2021 02:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Frequency Therapeutics, Inc....
Jul 08, 2021 11:30 am ET
DEADLINE ALERT for SPCE, FREQ, ACRX, and RLX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 08, 2021 10:00 am ET
FREQ, ACRX & RLX Shareholder Alert: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jul 07, 2021 11:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Array, ContextLogic, Ubiquiti, and Frequency and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Array Technologies, Inc. (NASDAQ: ARRY), ContextLogic, Inc. (NASDAQ: WISH),...
Jul 07, 2021 08:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FREQ
Pomerantz LLP announces that a class action lawsuit has been filed against Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ: FREQ) and certain of its officers. The class action, filed in the United States District Court for the...
Jul 06, 2021 11:30 am ET
DEADLINE ALERT for FREQ, ACRX, RLX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 04, 2021 10:55 am ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Frequency Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important August 2 Deadline in Securities Class Action – FREQ
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”), of the important August 2, 2021...
Jul 02, 2021 10:40 am ET
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors of a Securities Class Action Against Frequency, Inc. (NASDAQ: FREQ)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, reminds investors of a securities class action lawsuit against Frequency, Inc. (NASDAQ: FREQ) (“Frequency” or the “Company”) and its...
Jul 01, 2021 11:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ
NEW YORK, July 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ) and certain of its officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 21-cv-11040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Frequency's common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"), seeking to pursue remedies u
Jul 01, 2021 11:00 am ET
DEADLINE ALERT for SPCE, FREQ, ACRX, and RLX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 30, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Array, ContextLogic, Ubiquiti, and Frequency and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Array Technologies, Inc. (NASDAQ: ARRY), ContextLogic, Inc. (NASDAQ: WISH),...
Jun 30, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Frequency Therapeutics, Inc....
Jun 29, 2021 06:24 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Frequency Therapeutics, Inc. Investors With Losses Over $100K to Secure Counsel Before Important August 2 Deadline in Securities Class Action – FREQ
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”), of the important August 2, 2021...
Jun 29, 2021 11:25 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Frequency Therapeutics, Inc. (FREQ) Investors
LOS ANGELES, June 29, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"). Frequency investors have until August 2, 2021 to file a lead plaintiff motion.
Jun 29, 2021 09:00 am ET
FREQUENCY THERAPEUTICS INVESTORS: August 2, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the common
Jun 28, 2021 04:19 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FREQ
Pomerantz LLP announces that a class action lawsuit has been filed against Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ: FREQ) and certain of its officers. The class action, filed in the United States District Court for the...
Jun 28, 2021 11:00 am ET
DEADLINE ALERT for FREQ, ACRX, RLX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 25, 2021 06:30 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action – FREQ
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”), of the important August 2, 2021 lead plaintiff deadline.
Jun 25, 2021 10:08 am ET
FREQUENCY SHAREHOLDERS: August 2, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the common
Jun 24, 2021 12:30 pm ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)
BENSALEM, Pa., June 24, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming August 2, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period").
Jun 24, 2021 12:05 pm ET
DEADLINE ALERT for SPCE, FREQ, ACRX, and RLX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 24, 2021 10:00 am ET
FREQ Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) and certain of its officers, on behalf of...
Jun 23, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Array, ContextLogic, Ubiquiti, and Frequency and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Array Technologies, Inc. (NASDAQ: ARRY), ContextLogic, Inc. (NASDAQ: WISH),...
Jun 23, 2021 05:25 pm ET
Jun 23, 2021 02:10 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action Against Frequency Therapeutics, Inc. and Its Chief Executive Officer - FREQ
NEW YORK, June 23, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ) and certain of its officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 21-cv-11040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Frequency's common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"), seeking to pursue remedie
Jun 23, 2021 09:00 am ET
Robbins Geller Rudman & Dowd LLP Announces Upcoming Lead Plaintiff Deadline in the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ
Robbins Geller Rudman & Dowd LLP announces that purchasers of Frequency Therapeutics, Inc. (NASDAQ:FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”) have until August 2, 2021 to seek appointment as lead plaintiff in the Frequency Therapeu
Jun 22, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)
LOS ANGELES, June 22, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period").
Jun 21, 2021 11:30 am ET
DEADLINE ALERT for PINS, VWAGY, FREQ, ACRX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 21, 2021 10:35 am ET
FREQUENCY THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court f
NEW YORK, June 21, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of investors that purchased Frequency Therapeutics, Inc. (NASDAQ: FREQ) securities between November 16, 2020 and March 22, 2021, both dates inclusive (the "Class Period").
Jun 21, 2021 09:00 am ET
Frequency Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Frequency Therapeutics, Inc. (NASDAQ: FREQ) investors that acquired shares between November 16, 2020 and March 22, 2021. Investors have until July 13,...
Jun 18, 2021 07:00 pm ET
INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against Frequency Therapeutics, Inc.
The law firm of Kirby McInerney LLP announces that a securities class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired Frequency Therapeutics, Inc. (“Frequency” or the...
Jun 18, 2021 06:35 pm ET
Moore Kuehn, PLLC Encourages Investors of FREQ, ACRX, or OCGN to Contact Law Firm
NEW YORK, June 18, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false and/or misleading statements and/or failed to disclose, among other things, that:
Jun 18, 2021 11:00 am ET
FREQ Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Investors of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Frequency securities between November 16, 2020 and March 22, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Jun 17, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ:
Jun 16, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Array, ContextLogic, Ubiquiti, and Frequency and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Array Technologies, Inc. (NASDAQ: ARRY), ContextLogic, Inc. (NASDAQ: WISH),...
Jun 16, 2021 11:00 am ET
FREQ Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Frequency Therapeutics, Inc. (FREQ) Investors of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Frequency securities between November 16, 2020 and March 22, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Jun 15, 2021 08:15 pm ET
Jun 15, 2021 01:20 pm ET
SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Frequency Therapeutics, Inc. (FREQ) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) securities between November 16, 2020 and March 22, 2021, against the Company for remedies under the Securities Exchange Act of 1934. Frequency Therapeutic
Jun 15, 2021 12:55 pm ET
Frequency Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Frequency Therapeutics, Inc. (NASDAQ: FREQ) investors that acquired shares between November 16, 2020 and March 22, 2021. Investors have until July 13,...
Jun 15, 2021 11:30 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)
Law Offices of Howard G. Smith reminds investors of the upcoming August 2, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the “Class Peri
Jun 14, 2021 11:00 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Frequency Therapeutics, Inc. (FREQ) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ:
Jun 11, 2021 07:04 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Frequency Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important August 2 Deadline – FREQ
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021,...
Jun 11, 2021 01:25 pm ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ:
Jun 11, 2021 01:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Frequency Therapeutics, Inc. (FREQ) Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ:
Jun 11, 2021 12:42 pm ET
Portnoy Law: Lawsuit Filed On Behalf of Frequency Therapeutics, Inc. Investors
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) investors that acquired securities between November 16, 2020 and March 22,...
Jun 10, 2021 12:30 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Frequency Therapeutics, Inc. (FREQ) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”). Frequency investors have until August 2, 2021 to
Jun 10, 2021 12:22 pm ET
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors of a Securities Class Action Against Frequency, Inc. (NASDAQ: FREQ)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, reminds investors of a securities class action lawsuit against Frequency, Inc. (NASDAQ: FREQ) (“Frequency” or the “Company”) and its Chief Executive Officer, David Lucchino, alleging violations of §§
Jun 10, 2021 10:00 am ET
FREQ Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) and certain of its officers, on behalf of...
Jun 09, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Verus and Frequency, and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Verus International, Inc. (Other OTC: VRUS) and Frequency Pharmaceuticals, Inc....
Jun 09, 2021 02:55 pm ET
FREQUENCY THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court f
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of investors that purchased Frequency Therapeutics,...
Jun 09, 2021 11:00 am ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Frequency Therapeutics, Inc. (FREQ) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ:
Jun 08, 2021 08:00 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Frequency Therapeutics, Inc. (FREQ) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ:
Jun 08, 2021 04:27 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Frequency Therapeutics, Inc. (FREQ) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ: FREQ) investors concerning the Company’s possible violations of federal securities laws.
Jun 08, 2021 10:00 am ET
FREQ Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Encourages Investors to Contact the Firm
NEW YORK, June 8, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Frequency securities between November 16, 2020 and March 22, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/freq.
Jun 04, 2021 09:00 pm ET
FREQUENCY THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of investors that purchased Frequency Therapeutics, Inc. (NASDAQ:FREQ) securities between November 16, 2020 and March 22, 2021, both dates inclusive (the “Class Period”). Investors have until August 2, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jun 04, 2021 05:06 pm ET
SHAREHOLDER ALERT: Robbins LLP Announces that Frequency Therapeutics, Inc. (FREQ) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) securities between November 16, 2020 and March 22, 2021, against the Company for remedies under the Securities Exchange Act of 1934. Frequency Therapeutics is a phar
Jun 04, 2021 03:58 pm ET
Notice of Lead Plaintiff Deadline for Shareholders in the Frequency Therapeutics, Inc. Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the District of Massachusetts on behalf of purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”). The ca
Jun 04, 2021 03:31 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ:
Jun 04, 2021 11:00 am ET
FREQ BREAKING ALERT: Rosen Law Firm Encourages Frequency Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – FREQ
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 2, 2021.
Jun 04, 2021 10:34 am ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Frequency, Inc. (FREQ)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Frequency, Inc. (“Frequency” or “WPG”) (NASDAQ: FREQ) in the United States District Court for the District of Massachusetts on behalf of those who purchased or...
Jun 03, 2021 07:42 pm ET
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Frequency, Inc. (NASDAQ: FREQ)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit against Frequency, Inc. (NASDAQ: FREQ) (“Frequency” or the “Company”) and its Chief Executive Officer, David Lucchino, alleging violations of §§10(b) and 2
May 25, 2021 07:30 am ET
Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present at two upcoming investor conferences:
May 20, 2021 08:30 am ET
Frequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America’s Externally-Led Patient-Focused Drug Development Meeting to Address Sensorineural Hearing Loss
Frequency Therapeutics, Inc., (Nasdaq: FREQ) today shared a statement from David L. Lucchino, Frequency’s Chief Executive Officer, in support of the Hearing Loss Association of America (HLAA) and its efforts to advance the voice of the patient in leading the first-ever Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting on sensorineural hearing loss (SNHL).
May 18, 2021 01:48 pm ET
Scott+Scott Attorneys at Law LLP Announces Investigation into Frequency Therapeutics, Inc. (FREQ)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ: FREQ), or certain of its officers and directors, violated federal securities la
May 13, 2021 07:30 am ET
Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the first quarter ended March 31, 2021.
Apr 13, 2021 07:00 am ET
Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the expansion of its clinical development team with the addition of Jeffery T. Lichtenhan, Ph.D., a leading expert in hearing diagnostics and measurement.
Apr 09, 2021 07:00 am ET
Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the 20th Annual Needham Virtual Healthcare Conference.
Apr 01, 2021 10:11 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ:
Mar 30, 2021 04:30 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Frequency Therapeutics, Inc. (“Frequency” or “the Company”) (NASDAQ:
Mar 29, 2021 04:01 pm ET
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2020 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the fourth quarter and year ended December 31, 2020.
Mar 23, 2021 07:00 am ET
Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen
Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed in the study. Frequency also announced new data from a parallel study demonstrating hearing improvement from a single injection of FX-322. The Company plans to advance further development of FX-322 as a single dose r
Feb 22, 2021 04:00 pm ET
Frequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322
Findings from the Phase 1/2 study of FX-322, the company’s lead product candidate to treat SNHL, showed statistically significant increases in word recognition (WR) and words-in-noise (WIN) scores. Individuals with stable SNHL that received a single dose of FX-322 showed improvements in the number of words recognized in quiet from baseline to day 90 in the WR test (p=0.029) and the level of background noise in which words could be identified in the WIN test (p=0.012). There were no meaningful changes in the WR and WIN scores of the placebo group. FX-322 was also shown to be well tolerated. The
Feb 08, 2021 07:00 am ET
Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Kevin Franck, Ph.D., as Senior Vice President of Strategic Marketing and New Product Planning. Dr. Franck will lead pre-commercial strategy and launch planning for Frequency’s clinical pipeline, including its lead program aimed at developing a restorative treatment for sensorineural hearing loss (SNHL), the most common form of hearing loss.
Jan 19, 2021 07:30 am ET
Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Quentin McCubbin, Ph.D., as chief manufacturing officer. Dr. McCubbin will oversee Company technical operations, leading drug product formulation, chemistry manufacturing and controls (CMC) and supply chain, to support the development of Frequency’s pipeline of product candidates.
Jan 05, 2021 07:30 am ET
Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 39th annual J.P. Morgan Healthcare conference.
Dec 18, 2020 08:00 am ET
Frequency Therapeutics to Host Investor Event on the Potential for Restorative Treatments for Acquired Sensorineural Hearing Loss
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced plans to host a virtual event and live Q&A session on Tuesday, January 19, 2021 at 8:00 am ET.
Dec 01, 2020 07:30 am ET
Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer. Mr. Pfreundschuh will oversee the Company’s financial strategy and activities related to accounting, investor relations, business development and business operations.
Nov 16, 2020 07:30 am ET
Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2020 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the third quarter ended September 30, 2020.
Oct 29, 2020 07:00 am ET
Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today provided an update to its strategy and clinical development program for FX-322, its lead product candidate for the treatment of acquired sensorineural hearing loss (SNHL). SNHL is the primary cause of more than 90 percent of all hearing loss.
Sep 25, 2020 09:00 am ET
Frequency Therapeutics Appoints Cynthia Feldmann to its Board of Directors
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Cynthia Feldmann to its Board of Directors.
Sep 22, 2020 07:30 am ET
Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the completion of enrollment of its Phase 2a study of FX-322 for sensorineural hearing loss (SNHL). The company anticipates obtaining full results for the study, in which 95 patients were enrolled, in the second quarter of 2021.
Sep 13, 2020 03:00 pm ET
Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today presented clinical results from a longer-term durability study of FX-322, showing that some patients with chronic sensorineural hearing loss had significant improvement in key measures of hearing that were sustained for up to 21 months.
Sep 08, 2020 08:00 am ET
Frequency Therapeutics to Present at Upcoming Investor Conferences and Medical Meetings
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Company management will be presenting at the following investor conferences and medical meetings:
Aug 12, 2020 07:30 am ET
Frequency Therapeutics Provides Business Updates and Reports Second Quarter 2020 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the second quarter ended June 30, 2020.
Jul 17, 2020 04:05 pm ET
Frequency Therapeutics Announces $42 Million Private Placement
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has agreed to sell 2,350,108 shares of its common stock in a private placement to institutional and accredited investors. Institutional investors in the private placement included Wasatch Global, Federated Hermes Kaufmann Funds, RTW Investments, Perceptive Advisors, Driehaus Capital Management, Maven Investment Partners US and Alexandria Venture Investments, in ad
May 27, 2020 08:00 am ET
Frequency Therapeutics to Present at Upcoming Investor Conferences
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the Jefferies Virtual Healthcare Conference and participate in a “fireside chat” at the Goldman Sachs Annual Global Healthcare Conference. Details for each event are as follows:
May 14, 2020 07:30 am ET
Frequency Therapeutics Provides Business Updates and Reports First Quarter 2020 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the first quarter ending March 31, 2020.
May 14, 2020 07:15 am ET
Frequency Therapeutics Shares Clinical Data From Exploratory Study Confirming Delivery of FX-322 to the Cochlea
Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced top-line data from an exploratory clinical study designed to show whether drug levels of FX-322 in the cochlea can be directly measured. In addition to confirming the viability of the approach, study results showed measurable concentrations of FX-322 in every patient and that anatomical factors did not prevent the active agents of FX-322 from reaching the cochlea. Further, the levels of FX-322 in the cochlea were predicted to reach the therapeutically active range of the treatment.
Mar 26, 2020 07:00 am ET
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2019 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the fourth quarter and year ended December 31, 2019.
Feb 21, 2020 08:30 am ET
Frequency Therapeutics to Present at the 40th Annual Cowen Healthcare Conference
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the Cowen 40th Annual Healthcare Conference.
Feb 07, 2020 08:00 am ET
Frequency Therapeutics Expands Leadership Team with Newly Appointed Chief People Officer and Head of Intellectual Property
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced new appointments to its leadership team. Wendy Arnold has joined the company as Chief People Officer, and Lisa Geller, Ph.D., J.D., is the company’s new Head of Intellectual Property.
Jan 07, 2020 09:00 am ET
Frequency Therapeutics to Present Business and Pipeline Overview at the 38th Annual J.P. Morgan Healthcare Conference
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage
biotechnology company focused on harnessing the body’s innate biology to
repair or reverse damage caused by a broad range of degenerative
diseases, today announced that Chief Executive Officer David L. Lucchino
will present a Company overview at the 38th annual J.P.
Morgan Healthcare conference.
Nov 18, 2019 07:30 am ET
Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2019 Financial Results
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the third quarter ending September 30, 2019.
Oct 10, 2019 08:30 am ET
Frequency Therapeutics Commences Dosing in its Phase 2a Study of FX-322 for Sensorineural Hearing Loss; FDA Grants FX-322 Fast Track Designation
Frequency Therapeutics (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that dosing has commenced in a Phase 2a clinical study of FX-322, a locally administered investigational drug candidate designed to regenerate auditory hair cells and restore hearing function. The objectives of the Phase 2a study are to further establish the positive hearing signal observed in Frequency’s Phase 1/2 study of FX-322, as well as continue to evaluate safety and def
Oct 02, 2019 09:09 pm ET
Frequency Therapeutics Announces Pricing of Initial Public Offering
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $14.00 per share, for total gross proceeds of approximately $84.0 million, before deducting underwriting discounts and commissions. All of the common stock is being offered by Frequency. In addition, Frequency has granted the underwriters a 30-day option to purchas
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.